V

    VTYX (VTYX)

    Official site

    BIOTECHNOLOGY

    $14.00
    +0.00 (+0.00%)

    Last updated: Mar 04, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(12/17)
    Avg Surprise
    -34.89%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$-0.40
    Range$-0.51 - $-0.28
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.36+7.6%
    60d ago$-0.36+7.6%
    30d ago$-0.38+3.8%
    7d ago$-0.38+3.8%
    Current$-0.40
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-0.40---
    Sep 25
    Reported Nov 7
    		$-0.32$-0.45+28.89%Beat+36.0%
    Jun 25
    Reported Aug 7
    		$-0.38$-0.46+17.39%Beat+15.6%
    Mar 25
    Reported Jun 5
    		$-0.39$-0.69+43.48%Beat+37.1%
    Dec 24
    Reported Feb 27
    		$-0.41$-0.54+24.26%Beat+48.1%
    Sep 24
    Reported Nov 4
    		$-0.50$-0.52+3.85%Beat+45.7%
    Jun 24
    Reported Aug 9
    		$-0.45$-0.58+22.41%Beat+50.5%
    Mar 24
    Reported May 9
    		$-0.62$-0.69+10.14%Beat+8.8%
    Dec 23
    Reported Feb 27
    		$-0.79$-0.90+12.22%Beat-27.4%
    Sep 23
    Reported Nov 9
    		$-0.92$-0.90-2.22%Miss-55.9%
    Jun 23
    Reported Aug 10
    		$-0.91$-0.71-28.17%Miss-133.3%
    Mar 23
    Reported May 11
    		$-0.68$-0.65-4.62%Miss-51.1%
    Dec 22
    Reported Mar 23
    		$-0.62$-0.64+3.13%Beat-72.2%
    Sep 22
    Reported Nov 3
    		$-0.59$-0.44-34.09%Miss+81.4%
    Jun 22
    Reported Aug 15
    		$-0.39$-0.45+13.33%Beat+57.8%
    Mar 22
    Reported May 12
    		$-0.45$-0.52+13.46%Beat+51.3%
    Dec 21
    Reported Mar 23
    		$-0.36N/A+64.00%Beat-212.2%
    Sep 21
    Reported Nov 17
    		$-3.17$-0.36-780.56%Miss-2649.3%
    Mar 21
    Reported Jun 30
    		$-0.92$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-0.92$0.00N/AMiss-
    Mar 20
    Reported Jun 30
    		$-0.12$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-0.12$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.97
    SMA 20$13.96
    SMA 50$12.84
    SMA 200$6.40
    EMA 10$13.97
    EMA 20$13.86
    EMA 50$12.71
    EMA 200$7.81

    MACD

    Line: 0.27Signal: 0.37Hist: -0.10

    ADX

    ADX: 70.3+DI: 50.0-DI: 8.1

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down28.0
    PSAR$20.31

    Bollinger Bands

    Upper Band$14.00
    Lower Band$13.92
    %B Position61%(Middle)
    Band Width0.97

    RSI (14-Day)

    Overbought
    72.6

    Momentum Oscillators

    Stoch %K92.2
    Stoch %D82.7
    Williams %RN/A
    ROC (10d)0.3%
    Momentum0.04
    CCI (20d)185.6
    MFI (14d)70.9

    Volatility Measures

    ATR (14d)$0.15(1.1%)
    StdDev (20d)0.02
    Hist Vol2.1%(Low)

    Volume Flow

    VWAP$14.00
    OBV248.3M
    AD Line-88.5M
    CMF (20d)-0.070

    Volume Metrics

    Avg Vol (20d)3.3M
    Vol RatioN/A
    VWMA (20d)$13.96

    Pivot Points

    R3$14.01
    R2$14.01
    R1$14.00
    Pivot Point$14.00
    S1$13.99
    S2$13.99
    S3$13.98

    Advanced Oscillators

    TSI45.28
    Ultimate Osc48.7
    KST96.78

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$0$0$0$1.45M$0$0$0$1.08M$0$0$0$0
    Cost of Revenue$0$0$0N/A$0$0$0$403,000$0$0$0$150,000
    Gross Profit$0$0$0$724,000$0$0$0$673,000$0$0$0$-150,000
    Operating Expenses$24.87M$29.33M$30.10M$32.42M$38.55M$35.71M$41.77M$50.35M$57.95M$57.15M$42.55M$38.57M
    R&D$17.71M$22.27M$22.90M$24.82M$30.63M$27.80M$33.75M$42.02M$49.75M$48.56M$35.44M$30.18M
    SG&A$7.17M$7.07M$7.20M$7.60M$7.92M$7.91M$8.02M$8.33M$8.20M$8.59M$7.12M$8.39M
    Operating Income$-24,874,000$-29,333,000$-30,097,000$-32,418,000$-38,552,000$-35,712,000$-41,768,000$-50,346,000$-57,951,000$-57,145,000$-42,552,000$-38,571,000
    Interest Income$2.06M$2.37M$2.67M$3.06M$3.35M$3.78M$3.23M$3.62M$3.93M$3.90M$3.62M$3.19M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-22,829,000$-26,987,000$-27,440,000$-29,351,000$-35,249,000$-31,950,000$-38,572,000$-46,753,000$-54,027,000$-53,251,000$-38,931,000$-35,214,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-22,829,000$-26,987,000$-27,440,000$-29,351,000$-35,249,000$-31,950,000$-38,572,000$-46,753,000$-54,027,000$-53,251,000$-38,931,000$-35,214,000
    EBITDA$-24,558,000$-29,031,000$-29,750,000$-32,103,000$-38,290,000$-35,417,000$-41,391,000$-49,943,000$-57,694,000$-57,011,000$-42,419,000$-38,249,000
    EBIT$-24,884,000$-29,354,000$-30,106,000$-32,418,000$-38,599,000$-35,733,000$-41,799,000$-50,346,000$-57,959,000$-57,150,000$-42,553,000$-38,399,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VTYX

    News

    Bronstein, Gewirtz & Grossman, LLC Encourages Ventyx Biosciences

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ventyx Biosciences, Inc. (VTYX) securities. This investigation follows a 15.35% drop in Ventyx's stock price on December 2, 2025, after the company announced a delay in its Phase 2 study topline data release. The firm encourages affected investors to contact them for more information.

    The National Law Review•8/5/26•
    Somewhat-Bearish

    Ventyx Biosciences (VTYX) Jefferies Global Healthcare Conference Summary

    Ventyx Biosciences (VTYX) presented a summary of their Jefferies Global Healthcare Conference, highlighting advancements in their NLRP3 inhibitor program. The company showcased best-in-class safety and pharmacokinetic/pharmacodynamic profiles for their CNS-penetrant NLRP3 inhibitor, with plans for a Phase IIa study in Parkinson's disease. Additionally, preclinical studies demonstrated significant weight loss and metabolic improvements with NLRP3 inhibition, both as monotherapy and in combination with semaglutide, leading to planned Phase II obesity studies.

    Quartr•7/18/26•
    Somewhat-Bullish

    Ventyx Biosciences (VTYX) 2024 Wells Fargo Healthcare Conference Summary

    Ventyx Biosciences (VTYX) presented at the 2024 Wells Fargo Healthcare Conference, detailing its bifunctional approach with IBD and NLRP3 portfolios, including an S1P1 agonist and a Crohn's disease molecule in phase II studies. The company is advancing two NLRP3 compounds, VTX2735 and VTX3232, into phase II trials, with a particular focus on CNS immunology and neurodegenerative diseases. VTX3232, a CNS-penetrant NLRP3 inhibitor, showed promising phase I results with strong CNS exposure and the ability to suppress IL-1 beta in CSF, and is being explored for obesity and cardiometabolic benefits in upcoming phase II-A trials.

    Quartr•7/13/26•
    Somewhat-Bullish

    Ventyx Biosciences clarifies pipeline strategy, shares react to sector volatility

    Ventyx Biosciences is re-evaluating its autoimmune pipeline strategy following recent clinical setbacks, leading to investor focus on its cash runway and portfolio priorities. The company, which is NASDAQ-listed, operates in a volatile small-cap biotech segment and has seen its shares react to broader sector sentiment and regulatory updates affecting comparable biotechs. Analysts emphasize binary risks, cash needs, and potential dilution for such development-stage companies.

    Ad-hoc-news.de•6/26/26•
    Neutral

    Ventyx Biosciences Inc (VTYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Ventyx Biosciences Inc (VTYX), detailing its support and resistance levels, key technical indicators, and moving averages. The analysis suggests a "Buy" signal based on moving averages and a mixed signal from other indicators, with 3 buy signals and 1 sell signal.

    TradingKey•6/19/26•
    Neutral

    Frequently Asked Questions About VTYX

    Does VTYX pay dividends?
    VTYX (VTYX) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In